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Abstract
Chemoradiotherapy is a well-established treatment paradigm in oncology. There has been strong 
interest in identifying strategies to further improve its therapeutic index. An innovative strategy is 
to utilize nanoparticle (NP)chemotherapeutics in chemoradiation. Since the most commonly 
utilized chemotherapeutic with radiotherapy is cisplatin, the development of a NP cisplatin for 
chemoradiotherapy has the highest potential impact on this treatment. Here, we report the 
development of a NP comprised of polysilsesquioxane (PSQ) polymer crosslinked by a cisplatin 
prodrug (Cisplatin-PSQ) and its utilization in chemoradiotherapy using non-small cell lung cancer 
as a disease model. Cisplatin-PSQ NP has an exceptionally high loading of cisplatin. Cisplatin-
PSQ NPs were evaluated in chemoradiotherapy in vitro and in vivo. They demonstrated 
significantly higher therapeutic efficacy when compared to cisplatin. These results suggest that the 
Cisplatin-PSQ NP holds potential for clinical translation in chemoradiotherapy.
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Chemoradiotherapy, the concurrent administration of chemotherapy and radiotherapy, is part 
of the standard of care curative treatment for many difficult to treat solid cancers, including 
brain, head and neck, esophageal, gastric, pancreatic, lung, rectal, anal, and cervical 
cancers.1–5 Chemoradiotherapy has been shown to consistently improve local tumor control 
and rates of cancer cure compared to either sequential treatment or sole administration of 
chemotherapy or radiotherapy. Given its importance, one of the key aims in oncology 
research has been to identify agents and methods to improve chemoradiotherapy.6 Current 
approaches have focused on utilizing biologics to improve chemoradiotherapy. 
Unfortunately, the improvements have been modest. 7 Advances in drug delivery and 
nanomedicine have offered an unprecedented opportunity to improve chemoradiotherapy.8 
Nanoparticle (NP) possesses a unique biodistribution profile that is ideally suited for 
delivering chemotherapy agents for chemoradiotherapy. NPs preferentially accumulate in 
tumors through the enhanced permeability and retention (EPR) effect.9, 10 This leads to a 
higher intratumoral drug concentration when compared to their small molecule 
chemotherapeutic counterparts. Furthermore, NPs are unable to penetrate normal 
vasculatures and capillaries, leading to a lower dose to normal, healthy tissues near the 
tumor. This allows for a greater drug concentration differential between the tumor and 
surrounding normal tissue, which can translate into a higher therapeutic index. Indeed, 
preclinical studies have suggested that NP therapeutics are more effective than small 
molecule chemotherapeutics in chemoradiotherapy. 8, 11–13
The most commonly utilized chemotherapeutic in chemoradiation is cisplatin. 14, 15 While 
highly effective, its use and efficacy has been limited by toxicity.14 Therefore, improving 
cisplatin-based chemoradiotherapy will have the greatest clinical impact on 
chemoradiotherapy. We have recently developed a new NP platform, known as 
polysilsesquioxane (PSQ) NP, for the delivery of an oxaliplatin prodrug 16. We 
hypothesized that we can formulate a PSQ NP of cisplatin as an improved chemotherapeutic 
agent compared to cisplatin. This would also allow the PSQ NP platform to have a broader 
clinical indication. Herein, we report the synthesis and characterization of Cisplatin-PSQ NP 
with extremely high cisplatin loadings and trigger release properties. The NP was also post-
synthetically modified with a polyethylene glycol (PEG) shell to allow for superior in vivo 
performance. The potential of Cisplatin-PSQ NP in chemoradiotherapy was also 
demonstrated using non-small cell lung cancer (NSCLC) mouse models.
2. Materials and Methods
Materials
All chemicals were purchased from Fisher Scientific or Sigma-Aldrich and used without 
further purification unless noted. Cisplatin was purchased from AK Scientific. 
Tetrahydrofuran (THF) was distilled over sodium metal and benzophenone under nitrogen. 
Dimethylformamide (DMF) was dried by running through an activated alumina column. 
Thermogravimetric analysis (TGA) was performed using a Shimadzu TGA-50 equipped 
with a platinum pan and heated at 3 °C per minute in air. A JEM 100CX-2 transmission 
electron microscope (TEM) and a Hitachi S-4700 scanning electron microscope (SEM) were 
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used to determine particle size and morphology. TEM and SEM samples were prepared 
from ethanolic suspensions of the NPs dropped onto amorphous carbon coated copper grids 
or glass slides. The solvent was then allowed to evaporate. Dynamic light scattering (DLS) 
and zeta potential were measured using a Malvern Instrument Zetasizer Nano. Inductively-
coupled plasma mass spectrometry (ICP-MS) measurements were obtained using a Varian 
820-MS Inductively-Coupled Plasma Mass Spectrometer. ICP-MS samples were prepared 
by digesting a known amount of sample in concentrated nitric acid overnight, and then 
diluting with water to 2% nitric acid by volume.
NCI-H460 human NSCLC (ATCC# HTB-177), A549 human lung carcinoma cells (ATCC# 
CCL-185), and all cell culture reagents were purchased from the Tissue Culture Facility of 
the Lineberger Comprehensive Cancer Center at UNC-Chapel Hill.. All cells were 
maintained at 37 °C with 5% CO2 and were cultured according to ATCC recommendations. 
Mice (male nu/nu, 4–6 weeks old) were purchased from the animal colony at the UNC 
Lineberger Comprehensive Cancer Center. Mice were housed in an AALAC accredited 
facility in sterile housing at UNC-Chapel Hill. All animal work was approved and monitored 
by the UNC-Chapel Hill Institutional Animal Care and Use Committee.
Synthesis
Synthesis of c,c,t-Pt(NH3)2Cl2(propyltriethoxysilane succinic acid)2 (DSCP-Si)
—The platinum precursor complex c,c,t-Pt(NH3)2Cl2(OH)2 was synthesized from cisplatin 
according to a previously published method 17. Two hundred milligrams of c,c,t-
Pt(NH3)2Cl2(OH)2 (0.6 mmol) was suspended in 4 mL of anhydrous DMF. 700 μL of 3-
(triethoxysilyl)propyl succinic anhydride was then added (1.8 mmol). The resulting 
suspension was stirred under argon at 50 °C for 3 days, yielding a clear yellow solution. 
Two volume equivalents of triethylamine were added to precipitate the product. The product 
was isolated by centrifugation and washed twice with diethyl ether before drying under high 
vacuum, yielding a yellow brown crystalline material. The product was stored at −20 °C. 
Yield: 440 mg (78%). 1H NMR (DMSO-d6): 6.25(6H, NH3), 3.73 (12H, OCH2), 2.75 (4H, 
CH2), 2.31 (2H, CH), 1.45 (4H, CH2), 1.32 (4H, CH2), 1.12 (18H, CH3), 0.52 (4H, CH2).
Synthesis of Amino-Polyethylene-glycol (MW=5000) monomethyl ether 
(PEG5000-NH2)—Polyethylene glycol (PEG) (MW=5000) monomethyl ether (30 g) was 
dried under vacuum at 90 °C overnight. Anhydrous THF (360 mL) was added, followed by 
3.6 mL (46.5 mmol) of methanesulfonyl chloride. The solution was cooled to 0 °C on an ice 
bath and 6.9 mL triethylamine dissolved in 60 mL THF was added dropwise. The ice bath 
was removed, and the resulting solution was stirred under nitrogen at room temperature 
overnight. Water (150 mL) was added and the solution was cooled back to 0 °C. A sodium 
bicarbonate solution (1 M, 15 mL) and sodium azide (3.9 g, 60 mmol) were added. The THF 
was removed by rotary evaporation and the remaining aqueous solution was refluxed for 24 
hours. PEG-azide was extracted with dichloromethane (4×100 mL). The organic layers were 
collected, concentrated, and extracted with brine. The organic solution was then dried with 
magnesium sulfate, filtered, and then the dichloromethane was removed by rotary 
evaporation (21.2 g, 70% yield). 1H NMR (CDCl3) δ 2.93(2H), 3.33 (3H), 3.42 (3H), 3.50 
(4H), 3.53–3.75(410H), 3.77 (4H). The monomethyl PEG-azide complex (6.083 g) was 
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heated to 80 °C before being dissolved into 115 mL of THF and triphenylphosphine (3.174 
g, 12.1 mmol) was added. The solution was stirred at room temperature for 12 hours. Water 
(9.1 mL) was then added and the solution was stirred for 18 hours. The THF was removed 
by rotary evaporation and the residue was dissolved in water (150 mL), precipitating 
triphenylphosphine oxide. The triphenylphosphine byproducts were removed by filtration, 
and the water was removed by rotary evaporation. (3.95 g, 65% yield). 1H NMR (CDCl3): 
2.95 (2H), 3.32 (3H) 3.41(4H), 3.49 (4H), 3.50–3.70 (436H), 3.76 (4H).
Synthesis of Cisplatin-PSQ—DSCP-Si was dissolved in a mixture of ethanol, 
ammonium hydroxide solution (33%), and water (2:1:1.5). The resulting solution was stirred 
at room temperature in the dark for 1 hour. The resulting bluish white NP suspension was 
loaded onto a cation exchange column (Amberlite IRC-50) and the NPs were eluted using 
water. Residual impurities were removed by dialysis against water. Cisplatin-PSQ was 
isolated by centrifugation, washed with ethanol, and stored as an ethanolic suspension.
PEG Conjugation—Cisplatin-PSQ was suspended into acetonitrile at 1 mg/mL. To the 
Cisplatin-PSQ suspension, PEG5000-NH2 (1 mM), triethylamine (18 mM) and HBTU (8 
mM) were added. The suspension was stirred at room temperature for 24 hours before the 
NPs were isolated by centrifugation, and washed with acetonitrile twice and ethanol once. 
PEG-Cisplatin-PSQ was stored as an ethanolic suspension.
Platinum Release from Cisplatin-PSQ
400 mL of 2 mM HEPES buffer (pH=7.4) was placed in a 2-neck round bottom flask and 
then sparged with nitrogen gas and pre-warmed to 37 °C. Cisplatin-PSQ (2 mg, 1.84 μmol 
Pt) was suspended into 2 mL of the buffer solution. The NP suspension was then added to 
the large buffer sink and the system was incubated at 37 °C under a N2 blanket. Periodically, 
1.2 mL aliquots of the solution were removed. After 1 day of incubation, a solution of L-
cysteine in 2 mM HEPES buffer was added to make the total reducing agent concentration 
either 5 mM or 15 μM. The resulting system was incubated at 37 °C, with 1.2 mL aliquots 
periodically removed. The removed aliquots were processed by filtering the suspensions 
through a Costar Spin-X centrifuge tube filter (0.22 μm cellulose acetate). The filtrate was 
collected and analyzed by ICP-MS.
Cell Viability Assay Studies
A549 cells—A549 cells were plated in 6 well plates at 100,000 cells/well and incubated in 
3 mL media for 12 hours to promote cell attachment. The plates were washed once with 2 
mL PBS and subsequently given 2 mL media containing varying drug concentrations. The 
plates were incubated at 37 °C for 48 hours before the media was replaced with 2 mL of 
fresh media. The plates were incubated for an additional 24 hours before cell viability was 
determined by the trypan blue dye exclusion assay.
NCI-H460 cells—NCI-H460 cells were plated in 6 well plates at 300,000 cells/well and 
incubated in 3 mL media for 12 hours to promote cell attachment. The plates were then 
washed once with 2 mL PBS and subsequently given 2 mL of media containing varying 
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drug concentrations. The plates were incubated at 37 °C for 48 hours and cell viability was 
determined by the trypan blue dye exclusion assay.
Clonogenic Survival Assay-Chemoradiation Therapy
A549 cells in 10 cm2 plastic dishes were treated with 0.5 μM PEG-Cisplatin-PSQ or 
Cisplatin for 48 hours. After treatment, cells were washed with PBS, trypsinized, and seeded 
in 25 mL flasks at various densities. The flasks were then radiated immediately at 0, 2, 4, 6, 
or 8 Gy. Cells were incubated in the flasks for 10 days after irradiation. After incubation, 
cells were fixed in a 1:1 acetone:methanol mixture, and stained with trypan blue. All 
colonies with over 50 cells were counted. The relative cell surviving fraction was calculated 
by dividing the number of colonies of radiated cells by the number of cells plated, with a 
correction for the plating efficiency.
Tumor Efficacy Studies-Chemoradiation Therapy
Animal experiments were conducted in accordance to a protocol that was approved by the 
UNC Institutional Animal Use and Care review committee. A549 or NCI-H460 cells (1×106 
cells in 200 μL 1:1 RPMI-1640 and matrigel) were subcutaneously injected in the upper 
dorsal region of 6–8 week old Nu/Nu mice. Twelve days after inoculation, the mice were 
randomly distributed into different groups for subsequent treatment (PEG-Cisplatin-PSQ, 
free cisplatin, XRT only, and control) (7 mice per group). PEG-Cisplatin-PSQ or free 
cisplatin in PBS was tail vein i.v. injected at a dose of 1 mg cisplatin/kg. Six hours post 
injection, the tumors were subjected to a dose of 10 Gy with XRAD 320. Mice were 
shielded with a lead shield allowing radiation of the tumor site and minimal radiation to 
other organs. Tumor volumes were calculated by measuring two perpendicular diameters 
with a caliper and using the formula of V=0.5 × a × b2, where ‘a’ and ‘b’ are the larger and 
smaller diameters, respectively. The tumor volumes were measured every 2 days, and the 
relative percent change in tumor volume was calculated using the relation 100* (Vi−Vo)/Vo, 
where Vi is the volume calculated and Vo is the initial volume on day 1. Tumor volumes 
were compared at the end of the study using student t-test.
3. Results
Nanoparticle Synthesis
Cisplatin-PSQ NPs were synthesized via a base catalyzed sol-gel polymerization in a 
mixture of ethanol, water, and ammonia before purification by ion-exchange 
chromatography, dialysis, and centrifugation (Figure 1). These synthesis conditions are 
similar to those used in Stöber-type synthesis used to make monodisperse colloidal silica 
NPs.18, 19 The isolated NPs were characterized by transmission electron microscopy (TEM), 
scanning electron microscopy (SEM), dynamic light scattering (DLS), thermogravimetric 
analysis (TGA) and inductively coupled plasma-mass spectrometry (ICP-MS). Cisplatin-
PSQ NPs have a diameter of 50–100 nm by both SEM and TEM (Figures 2A and 2B), but 
exhibit hydrogel-like behavior under physiological conditions, swelling to a DLS diameter 
(Z average) of 134.2 nm (Figure 2C, Table 1). TGA of Cisplatin-PSQ (Figure 2D) gives the 
expected weight loss for the completely condensed NP, indicating that Cisplatin-PSQ is a 
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homopolymer of DSCP-Si. ICP-MS measurements of the platinum content give a loading of 
42 wt% cisplatin, confirming the TGA measurements.
Platinum Release from Cisplatin-PSQ
The platinum release from Cisplatin-PSQ was measured in the absence or presence of L-
cysteine, a model reducing agent (Figure 3A). In the absence of any reducing agent (t<0 
hrs), only 9–15% of the total platinum is released, most likely from weakly physisorbed 
DSCP-Si on the NP surface which was quickly released after submersion in the buffer. After 
the addition of 15 μM L-cysteine, similar to the bloodstream thiol concentration, only a 
small amount of additional platinum is released over 73 hours of incubation. In contrast, 
platinum release is much more rapid in the presence of 5 mM L-cysteine, corresponding to 
the intracellular thiol concentration. All of the cisplatin payload was released in less than 48 
h in the presence of 5 mM L-cysteine.
Post-synthetic modification of Cisplatin-PSQ
Amine-terminated polyethylene glycol (MW=5000) is coupled to the surface of Cisplatin-
PSQ by an amide bond. The morphology of the NPs was unchanged by electron microscopy 
(Supporting Information), but the PEG-Cisplatin-PSQ NPs are 150 nm in diameter by DLS 
(Z average, Figure 2C, Table 1). The increase in hydrodynamic size is due to the polymer 
chains extending away from the NP surface. The zeta potential of PEG-Cisplatin-PSQ 
increased to −6.5 mV.
In vitro evaluation of PEG-Cisplatin-PSQ
PEG-Cisplatin-PSQ was evaluated in vitro against A549 and H460 lung cancer cells (Figure 
3B and 3C). PEG-Cisplatin-PSQ has an IC50 of 14.9 μM against A549 cells and an IC50 of 
2.07 μM against H460 cells, which are higher than those of cisplatin under the same 
conditions (IC50 of 3.5 μM against A549 cells and IC50 of 0.65 μM against H460 cells). 
PEG-Cisplatin-PSQ was also evaluated in vitro as a radiosenstizer (Figure 3D) against A549 
cells. A549 cells were treated with 0.5 uM cisplatin or PEG-Cisplatin-PSQ, containing the 
equivalent of 0.5 uM cisplatin,48 hours before being treated with varying doses of radiation. 
Cells treated with either platinum formulation plus radiation demonstrated less survival in a 
clonogenic assay than cells treated with radiation alone. This was consistent over all 
radiation dose levels tested.
In vivo evaluation of PEG-Cisplatin-PSQ in chemoradiotherapy
PEG-cisplatin-PSQ was studied in in vivo in chemoradiotherapy in two mouse lung cancer 
xenograft models (Figures 4A and 4B). Mice received either no treatment, 10 Gy of 
radiotherapy, cisplatin (1 mg/kg) 6 hours prior to 10 Gy radiation, or PEG-Cisplatin-PSQ (1 
mg cisplatin/kg) 6 hours prior to 10 Gy radiation. For the A549 xenograft model (Figure 
4A), cisplatin treatment arm did not show any significant effects (p ≥0.05) over radiation 
alone over the course of the study, while PEG-cisplatin-PSQ demonstrated a significant (p 
≤0.05) increase in efficacy over radiation alone from day 8 onwards as well as a significant 
improvement over cisplatin on day 22. The endpoint time (5x tumor volume increase for 1 
mouse in group) was extended from 22 days for radiation only to 30 days for PEG-Cisplatin-
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PSQ plus radiotherapy. For the H460 xenograft model (Figure 4B), cisplatin demonstrated 
insignificant radiosensitization effects over the course of the study. PEG-Cisplatin-PSQ 
demonstrated statistically significant (p ≤0.05) increases in tumor growth inhibition over 
radiation alone over the entire study period and over cisplatin plus radiation from days 4–8 
to days 14–16.
Discussions
The central aim of our study was to engineer a NP formulation of cisplatin that can improve 
the therapeutic efficacy of cisplatin-based chemoradiotherapy. We formulated the Cisplatin-
PSQ NP and demonstrated that it has excellent physical properties (size and surface charge) 
for targeting tumors.20 The size expansion of the PSQ NPs is due to the repulsive effects of 
the negatively charged silanols and carboxylic acids in the PSQ matrix, reflected in the 
highly negative zeta potential of Cisplatin-PSQ (Table 1). The Cisplatin-PSQ also has very 
high drug loading. This platinum loading corresponds to approximately 1.15×105 cisplatin 
molecules/NP and is several orders of magnitude higher than similar NP systems.21–25 The 
previously reported oxaliplatin-PSQ NPs have a comparable platinum loading on a number 
basis.16
One of the unique properties of Cisplatin-PSQ NP is its stability under normal physiological 
conditions. The NP is composed of large quantities of platinum (IV) centers, which are 
kinetically inert and must be reduced by biomolecules for the active platinum (II) complex 
to be released from the NP matrix in order to exert their antitumor activity (Figure 1). 
However, we expect Cisplatin-PSQ NPs to release cisplatin more rapidly within the tumor 
microenvironment or upon cellular internalization, where higher concentrations of reducing 
agents are present. Our drug release results have confirmed our hypothesis and that the 
Cisplatin-PSQ NPs would show minimal drug release in circulation, but when placed in a 
highly reducing environment, such as the tumor microenvironment or upon cellular 
internalization, cisplatin would be rapidly released from the PSQ matrix, leading to more 
pronounced antitumor effects.
For in vivo applications, we modified the Cisplatin-PSQ NP with polyethylene glycol 
(PEG). PEG is an inert, biocompatible polymer which is widely used to improve the 
biocompatibility, reduce mononuclear phagocytic system (MPS) uptake, and improve 
efficacy of nanomaterials.26–28 The presence of numerous carboxylic acids on the surface of 
Cisplatin-PSQ allows the NPs to be post-synthetically modified through standard amide 
coupling chemistry. The increase in surface charge of post-modified NPs is indicative of the 
neutral PEG chains shielding the NP surface charge and the replacement of anionic 
carboxylic acids with neutral amide linkages. Extrapolating TGA measurements (Figure 2D) 
gives a PEG coverage of 1 PEG/4.5 nm2, which correlates to PEG in a brush confirmation 
extending away from the NP surface, which should impart sufficient stealth characteristics 
to the NPs. 29
In vitro evaluation of PEG-Cisplatin-PSQ as a chemotherapeutic and a radiosensitizer 
showed lower efficacy than that of cisplatin. This is presumably due to the presence of the 
PEG corona that can reduce the non-specific uptake of the NPs by the cancer cells, lowering 
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the intracellular cisplatin concentrations. The reducing power of standard cell media is quite 
low, so we would also expect minimal drug release in media. Our data is consistent with 
other NP formulations’ result in vitro.30
In contrast to in vitro results, PEG-Cisplatin-PSQ is significantly more effective than 
cisplatin in chemoradiotherapy. These results confirmed our hypothesis that NP 
formulations can improve chemoradiotherapy. It also suggest that PEG-Cisplatin-PSQ NPs 
hold high potential for clinical translation. The lack of therapeutic efficacy of small 
molecule cisplatin is likely due to the very low dose of drug we administered in this study. 
This also highlights the potency of PEG-Cisplatin-PSQ as a radiosensitizer. PEG-Cisplatin-
PSQ presumably is able to accumulate in tumors more than cisplatin, which would allow the 
NP to exert a greater therapeutic effect. Studies are ongoing to further elucidate the 
pharmacokinetics, efficacy, and toxicity of PEG-Cisplatin-PSQ as a radiosensitizer and as a 
chemotherapy agent.
In summary, we have synthesized a novel NP formulation of cisplatin using base-catalyzed 
sol-gel polymerization. The Cisplatin-PSQ NPs have exceptionally high drug loading, and 
can be post-synthetically modified to possess a PEG surface. PEG-Cisplatin-PSQ was 
evaluated in vitro and in vivo in chemoradiotherapy using murine models of non-small cell 
lung cancer. PEG-Cisplatin-PSQ demonstrated higher therapeutic efficacy than cisplatin. 
These results suggest that Cisplatin-PSQ is a promising cancer therapeutic with the potential 
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Schematic of the synthesis and triggered drug release of Cisplatin-PSQ nanoparticles for 
tumor growth inhibition.
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a) SEM image of Cisplatin-PSQ NPs (scale bar = 100 nm). b) TEM image of Cisplatin-PSQ 
NPs (scale bar = 50 nm). c) Number weighted DLS curves for Cisplatin-PSQ (blue) and 
PEG-Cisplatin-PSQ (red) taken in 5mM PBS (pH=7.4). d) TGA curves of Cisplatin-PSQ 
(blue) and PEG-Cisplatin-PSQ (red).
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A) Percentage platinum release from Cisplatin-PSQ in the presence of high (5 mM, red line) 
or low (15 μM, blue line) concentrations of L-cysteine. The reducing agent was added at 
time 0, indicated by the black arrow. B) Cell viability curves of cisplatin (red, IC50=3.49 
μM) and PEG-Cisplatin-PSQ (blue, IC50= 14.91 μM) evaluated in A549 lung cancer cells. 
C) Cell viability curves of cisplatin (red, IC50=0.65 μM) and PEG-Cisplatin-PSQ (blue, 
IC50= 2.07 μM) evaluated in H460 lung cancer cells. D) In vitro colony forming assay of 
A549 cells treated with varying doses of radiation only (green), 0.5 uM cisplatin + radiation 
(red) and 0.5 uM of cisplatin in PEG-Cisplatin-PSQ + radiation (blue).
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A) In vivo chemoradiotherapy efficacy assay against mice bearing A549 xenografts. C) In 
vivo chemoradiotherapy efficacy assay against mice bearing H460 xenografts. Mice received 
either saline control (black), 10 Gy radiation (red), cisplatin (1 mg/kg) 6 hours prior to 10 
Gy radiation (green) or PEG-Cisplatin-PSQ (1 mg cisplatin/kg) 6 hours prior to 10 Gy 
radiation (blue).
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